

# RFD

DOSSIER  
UNDER DEVELOPMENT



PRODUCT NAME	PHARMACEUTICAL FORM	STRENGTH	REFERENCE	THERAPEUTIC CLASS	DOSSIER AVAILABILITY
<b>ALIMENTARY TRACT &amp; METABOLISM</b>					
1. Sitagliptin hydrochloride	Film-coated tablets	25 mg   50 mg   100 mg	Januvia/Merck	Oral antidiabetic	2017 DEC
2. Sitagliptin hydrochloride + Metformin	Film-coated tablets	50 mg + 500 mg   50 mg + 850 mg   50 mg + 1000 mg	Janumet/Merck	Oral antidiabetic	2018 Q1
3. Linagliptin* <b>NEW!</b>	Film-coated tablets	5 mg	Trajenta/ Boehringer Ingelheim	Oral antidiabetic	2019 Q1
<b>ANTINEOPLASTIC &amp; IMMUNOMODULATING AGENTS</b>					
4. Lenalidomide	Capsules	2.5 mg   5 mg   7.5 mg   10 mg   15 mg   25 mg	Revlimid/ Celgene	Multiple myeloma	2018 Q3
<b>BLOOD &amp; BLOOD FORMING ORGANS</b>					
5. Rivaroxaban*	Film-coated tablets	2.5 mg   10 mg   15 mg   20 mg	Xarelto/Bayer	Oral anticoagulant	2017 DEC
6. Ticagrelor**	Film-coated tablets	60 mg   90 mg	Brilique/ AstraZeneca	Platelet aggregation inhibitor	2017 DEC
7. Apixaban*	Film-coated tablets	2.5 mg   5mg	Eliquis/Bristol- -Myers Squibb	Oral anticoagulant	2018 Q4
<b>CARDIOVASCULAR SYSTEM</b>					
8. Amlodipine maleate + Valsartan + Hydrochlorothiazide*	Film-coated tablets	10 mg + 160 mg + 12.5 mg   10 mg + 160 mg + 25 mg   10 mg + 320 mg + 25 mg   5 mg + 160 mg + 12.5 mg   5 mg + 160 mg + 25 mg	Exforge HCT/ Novartis	Calcium-channel blocker & angiotensin-II antagonist & diuretic combination	2017 DEC
<b>DERMATOLOGICALS</b>					
9. Equisetum arvense + Methylsulfonylmethane + Hydroxypropylchitosan	Water-soluble nail lacquer	not applicable	Sililevo/Taurus Pharma	Medical device - nail strengthener	2018 Q2
<b>NERVOUS SYSTEM</b>					
10. Dimethyl fumarate	Gastro-resistant hard capsules	120 mg   240 mg	Tecfidera/ Biogen Idec	Multiple sclerosis	2018 Q2
11. Metamizole <b>NEW!</b>	Film-coated tablets	500 mg	Novalgin/ Sanofi Aventis	Pain treatment	2018 Q3

\* Polpharma Group API

\*\* Polpharma Group API + US dossier available

For more information and up-dates regarding available dossiers and dossiers in development, please contact your assigned Sales Manager or our Commercial Department. Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

## CONTACT

### POLPHARMA GROUP PHARMACEUTICAL WORKS

Pelplińska 19  
83-200 Starogard Gdański  
Poland  
Phone: +48 58 563 16 00  
Fax: +48 58 562 23 53  
www.polpharma.pl

### POLPHARMA B2B STRATEGIC PARTNER, FARMAPROJECTS

Carrer Provença 392, 6ª Planta  
08025 Barcelona (Spain)  
Phone: +34 93 508 05 00  
Fax: +34 93 508 05 01  
e-mail: salesb2b@polpharma.com  
www.polpharmab2b.com

Meet us on LinkedIn:

**LinkedIn**®

[www.linkedin.com/company/polpharma-b2b](http://www.linkedin.com/company/polpharma-b2b)